Literature DB >> 8652457

Management of paralytic lagophthalmos with a modified gold-weight implantation technique.

G J Gladstone1, F A Nesi.   

Abstract

A modified gold-weight implantation technique was used to treat paralytic lagophthalmos in 15 patients. Three patients had suffered extrusions of previously placed gold-weight implants, two had other complications necessitating reoperation, and 10 had no previous surgery. The surgical modifications were intended to reduce the incidence of implant extrusion, postoperative ptosis, and implant visibility beneath the skin. The important changes in the surgical technique included (a) advancing the levator aponeurosis over the implant and (b) adjusting the final eyelid height intraoperatively with levator myotomies. Follow-up ranged from 6 to 11 months. None of the patients in this study had postoperative problems associated with ptosis, implant extrusion, or implant visibility. Mild, prolonged, postoperative edema was noted in several patients. This resolved spontaneously. Mild eyelid retraction and lagophthalmos were seen postoperatively in two patients. This was caused by a failure to perform marginal myotomies at the time of the initial surgeries.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652457     DOI: 10.1097/00002341-199603000-00006

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  2 in total

1.  The impact of implantation site on procedure success in patients with unresolved facial palsy treated with upper-eyelid gold weight loading.

Authors:  Izabela Nowak-Gospodarowicz; Robert Koktysz; Marek Rękas
Journal:  Sci Rep       Date:  2022-07-13       Impact factor: 4.996

2.  The Role of Gold Weight Implants in the Management of Paralytic Lagophthalmos.

Authors:  Muammer Melih Şahin; Eray Uzunoğlu; Recep Karamert; Süleyman Cebeci; Gökçen Cesur; Mücahit Yalçin; Mehmet Düzlü; Hakan Tutar; Mehmet Birol Uğur; Alper Ceylan
Journal:  Turk J Med Sci       Date:  2021-06-27       Impact factor: 0.973

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.